Retatrutide

Overview

Retatrutide (development code LY3437943, informally "Triple G") is a single-molecule agonist that activates three incretin and metabolic receptors at once: GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and the glucagon receptor. It is being developed by Eli Lilly as a once-weekly subcutaneous injection for obesity and related cardiometabolic conditions.

It represents the next conceptual step beyond the dual GIP/GLP-1 agonist tirzepatide (Mounjaro/Zepbound): where tirzepatide hits two receptors, retatrutide adds glucagon-receptor activity, which appears to push weight loss into a new range.

Regulatory status (as of mid-2026): Retatrutide is investigational and not approved by the FDA or any major regulator. Lilly has signaled intent to file, but no confirmed submission date, PDUFA date, or expedited-program designation has been publicly documented in a primary regulatory source. Treat any specific approval timeline you see online as speculation.

Mechanism

Each of the three receptor targets contributes a distinct effect, and the combination is the point:

• GLP-1 — suppresses appetite, slows gastric emptying, and enhances glucose-dependent insulin secretion. This is the backbone shared by semaglutide and tirzepatide.
• GIP — complements GLP-1 with additional insulinotropic and appetite-modulating effects, and may improve tolerability of the GLP-1 component.
• Glucagon — the differentiator. Glucagon-receptor agonism increases energy expenditure and promotes hepatic fat oxidation. Historically, glucagon's tendency to raise blood glucose made it hard to use therapeutically; pairing it with potent GLP-1/GIP activity offsets that, so the net effect is increased calorie burn and improved glycemia.

The working hypothesis is that GLP-1 and GIP reduce energy intake while glucagon raises energy expenditure — attacking the energy-balance equation from both sides. The glucagon arm is also of particular interest for liver fat, which is reflected in the dedicated MASLD trial below.

Clinical Data

Phase 2 — NEJM 2023 (the foundational human trial)

The pivotal Phase 2 trial (Jastreboff AM, Kaplan LM, Frías JP, et al., New England Journal of Medicine, 2023; NCT04881760) randomized 338 adults with obesity to retatrutide (1, 4, 8, or 12 mg) or placebo:

• 24.2% mean body-weight reduction at the 12 mg dose over 48 weeks
• Clear dose-dependent response across all cohorts
• Improvements in fasting glucose, triglycerides, and blood pressure
• Mostly mild-to-moderate, dose-related gastrointestinal side effects

At the time, 24.2% was the highest weight-loss figure reported for any pharmacological agent in a trial of this kind.

Phase 3 — the TRIUMPH program

The Phase 3 registrational program is named TRIUMPH and comprises four trials (design and rationale published in Diabetes, Obesity & Metabolism, 2026):

| Trial | Population | Duration | Status (mid-2026) | |---|---|---|---| | TRIUMPH-1 | Obesity/overweight without type 2 diabetes (nested OSA and knee-OA sub-studies) | 80 weeks | Topline reported May 2026 | | TRIUMPH-2 | Obesity/overweight with type 2 diabetes | 80 weeks | Ongoing | | TRIUMPH-3 | Class II/III obesity with established cardiovascular disease | 80 weeks | Ongoing | | TRIUMPH-4 | Obesity/overweight with knee osteoarthritis | 68 weeks | Topline reported Dec 2025 |

TRIUMPH-4 topline (December 2025): In 445 participants with knee osteoarthritis, the 12 mg dose produced an average 28.7% body-weight reduction (≈32 kg) at 68 weeks, alongside substantial osteoarthritis pain relief (WOMAC pain reduced by up to ~75%), with more than 1 in 8 treated patients reporting complete freedom from knee pain at trial end.

TRIUMPH-1 topline (May 2026): In the pivotal obesity trial, 80-week weight loss was 19.0% (4 mg), 25.9% (9 mg), and 28.3% (12 mg) versus 2.2% for placebo. Roughly 45% of 12 mg patients lost ≥30% of their body weight. In an extended-follow-up subgroup (baseline BMI ≥35), weight loss reached up to 30.3% by 104 weeks.

Important caveat: As of mid-2026, the TRIUMPH-1 and TRIUMPH-4 efficacy results are topline figures from Lilly press releases and conference presentations, not yet full peer-reviewed publications. TRIUMPH-2 (type 2 diabetes) and TRIUMPH-3 (cardiovascular disease) had not publicly read out their primary efficacy results at the time of writing. Final peer-reviewed numbers can differ from topline announcements.

Liver fat — Phase 2a MASLD trial (Nature Medicine 2024)

A dedicated Phase 2a trial in metabolic dysfunction-associated steatotic liver disease (MASLD/NAFLD), published in Nature Medicine (2024), reported large reductions in liver fat content with retatrutide — consistent with the glucagon component's role in hepatic fat oxidation. This positions retatrutide as a candidate not just for weight loss but for fatty-liver disease.

How It Compares

| Agent | Receptors | Reported peak trial weight loss | |---|---|---| | Semaglutide (Wegovy) | GLP-1 | ~15% (STEP 1, 68 wk) | | Tirzepatide (Zepbound) | GIP + GLP-1 | ~21–23% (SURMOUNT-1, 72 wk) | | Retatrutide (investigational) | GIP + GLP-1 + glucagon | ~28–30% (TRIUMPH topline) |

The trend across these molecules is clear: adding receptor targets has, so far, increased the ceiling on weight loss. Retatrutide's glucagon arm is the current frontier.

Research Notes & Cautions

• All human efficacy data are industry-sponsored (Eli Lilly). There is no independent confirmation outside Lilly's clinical program.
• The glucagon component warrants monitoring — transient heart-rate increases are reported, and the long-term cardiovascular safety profile is precisely what TRIUMPH-3 is designed to evaluate. It has not yet read out.
• Trial dosing uses a slow, structured escalation (starting at low milligram doses and titrating upward over months) specifically to manage gastrointestinal tolerability. Community protocols that escalate faster are extrapolations and carry meaningful risk of nausea, vomiting, and dehydration.
• Because retatrutide is investigational, any non-trial material is, by definition, not pharmaceutical-grade and not quality-controlled.

Bottom Line

Retatrutide is the most closely watched compound in the obesity space heading into a likely regulatory filing. The Phase 2 result (24.2%) has been reinforced by Phase 3 topline figures approaching 28–30%, with added signals in osteoarthritis pain and liver fat. The key open questions — full peer-reviewed Phase 3 data, the cardiovascular outcomes trial (TRIUMPH-3), the diabetes trial (TRIUMPH-2), and the FDA review — remain unresolved as of mid-2026.